Who are Sofosbuvir, Ribavirin, and Stribild's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Glecaprevir / Pibrentasvir Oral Tablet [Mavyret], Daclinza and Sunvepra, Grazaoprevir/Elbasavir, ABT450r-ABT267-ABT333 +/- Ribavirin, Grazaoprevir/Elbasavir/RBV, Zepatier plus Sofosbuvir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sofosbuvir-ribavirin-and-stribild.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Sofosbuvir, Ribavirin, and Stribild — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sofosbuvir, Ribavirin, and Stribild (Sofosbuvir, Ribavirin, and Stribild) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA) combination; antiretroviral combination. Area: Virology/Infectious Disease.

marketed Direct-acting antiviral (DAA) combination; antiretroviral combination HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase Virology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Sofosbuvir, Ribavirin, and Stribild (Sofosbuvir, Ribavirin, and Stribild) — Saint Michael's Medical Center. This combination targets hepatitis C virus (HCV) through multiple mechanisms: sofosbuvir inhibits viral RNA polymerase, ribavirin is a nucleoside analog that disrupts viral replication, and Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) is an antiretroviral combination for HIV co-infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sofosbuvir, Ribavirin, and Stribild TARGET	Sofosbuvir, Ribavirin, and Stribild	Saint Michael's Medical Center	marketed	Direct-acting antiviral (DAA) combination; antiretroviral combination	HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
Daclinza and Sunvepra	Daclinza and Sunvepra	Pusan National University Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein
ABT450r-ABT267-ABT333 +/- Ribavirin	ABT450r-ABT267-ABT333 +/- Ribavirin	Ottawa Hospital Research Institute	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease, NS5A protein, NS5B polymerase
Grazaoprevir/Elbasavir/RBV	Grazaoprevir/Elbasavir/RBV	The HIV Netherlands Australia Thailand Research Collaboration	marketed	Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog	HCV NS3/4A protease; HCV NS5A protein; viral RNA polymerase
Zepatier plus Sofosbuvir	Zepatier plus Sofosbuvir	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) combination; antiretroviral combination class)

Saint Michael's Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sofosbuvir, Ribavirin, and Stribild — Competitive Intelligence Brief. https://druglandscape.com/ci/sofosbuvir-ribavirin-and-stribild. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing